Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Two-Year TAXUS-IV Stent Data Show Slight Increase In Thrombosis

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific's Taxus drug-eluting stent is associated with slightly greater long-term thrombosis than the bare-metal Express in the TAXUS-IV study

You may also be interested in...

Thrombosis Events May Be Clarified By e-CYPHER Data Expected In February

FDA's public health notification related to adverse events for J&J/Cordis' Cypher is intended to generate further data collection for the drug-eluting stent rather than raise undue concern over clotting issues, the agency says

ACC In Brief

TAXUS II: Anti-restenotic effects of paclitaxel are maintained beyond the cessation of clopidogrel therapy at six months post-implant, according to twelve-month data from Boston Scientific's trial of the Taxus paclitaxel-eluting stent, presented March 27 by Antonio Columbo, MD, Centro Cuore Columbus, Milan. Target lesion revascularization rates were 4.7% and 3.8% in the slow drug-release and moderate drug-release groups, respectively at 12 months, compared with 14.4% in the control group. One-year follow-up results represent a slight increase in each group over the six-month TLR rates presented in September at the annual TCT meeting in Washington, D.C. (1"The Gray Sheet" Sept. 30, 2002, p. 5)...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts